NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2
June 29, 2023 at 03:02 pm EDT
Share
(via NewsDirect)
NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share news about the beginning of clinical trials for its broad-spectrum antiviral drug NV-CoV-2. This is with two oral drug products NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies.
Diwan told Proactive the Phase 1a/1b safety and efficacy clinical trial began June 17th and is aimed at satisfying the as-yet-unmet medical need for a highly effective broad-spectrum, pan-coronavirus drug that can be used for all patient populations. The trial will use patients with mild to moderate COVID-19 to assess indication of efficacy.
Contact Details
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.